Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCardia Inc BCDA

Healthcare Biotechnology
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and... see more

Recent & Breaking News (NDAQ:BCDA)

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

GlobeNewswire March 1, 2022

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

GlobeNewswire February 14, 2022

BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

Business Wire February 3, 2022

BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire January 10, 2022

BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates

GlobeNewswire December 15, 2021

BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire November 10, 2021

BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021

GlobeNewswire November 8, 2021

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

GlobeNewswire October 21, 2021

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies

GlobeNewswire October 12, 2021

BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial

GlobeNewswire October 7, 2021

BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)

GlobeNewswire October 6, 2021

CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021

GlobeNewswire September 10, 2021

BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

GlobeNewswire September 9, 2021

BioCardia Signs Exclusive Development Agreement With AstraZeneca

GlobeNewswire July 25, 2019

BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange

GlobeNewswire June 6, 2019

Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia's Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

GlobeNewswire May 23, 2019

BioCardia Reports 2019 First Quarter Financial Results and Business Highlights

GlobeNewswire May 20, 2019

BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart

GlobeNewswire May 8, 2019